BPC-157 is a synthetic peptide that is the subject of research into tissue regeneration processes, cell protection, and the functioning of various organ systems in the body. Previous experiments have included the gastrointestinal, nervous, cardiovascular, and muscular-skeletal systems, among others.
Most of the described results come from preclinical studies, primarily conducted on rats and mice. Although some observations point to interesting biological mechanisms, this does not mean that similar effects have been confirmed in humans.
The article presents the properties of BPC-157, its pharmacokinetics, chemical stability, and the most important directions of research on this peptide.
What is the BPC-157?
BPC-157, that is Body Protection Compound 157, It is a synthetic pentadecapeptide composed of 15 amino acids. Its sequence was developed based on a fragment of a protein associated with human gastric juice.
The molecular mass of BPC-157 is approximately 1419 Da. In the literature, designations BPC-15, PL-10, PLD-116 and PL14736 can also be found.
This peptide is primarily studied for its role in the repair processes occurring in tissues. Animal experiments included damage to tendons, ligaments, muscles, the gastrointestinal tract, and the nervous system [1, 2].
The studies also analyzed its effects on the liver, the heart, the pancreas, the cornea of the eye, and the mucous membrane of the digestive tract.
Particular interest is aroused by observations regarding cytoprotection, i.e., the protection of cells from certain types of damage, and the modulation of inflammatory processes.
However, it is necessary to distinguish the biological activity observed in experimental models from the confirmed therapeutic effect in humans.
Studied forms and routes of administration of BPC-157
Various formulations are mentioned in the literature and materials related to BPC-157, including oral, transdermal, topical, and parenteral formulations [3].
In preclinical studies, oral, intra-muscular, intrathecal, and local administration were used, among others. The choice of administration route depended on the design of the experiment and the biological model being studied.
The route of administration can influence the absorption of the substance, its availability in the circulation, and its distribution in tissues. However, this does not mean that all of the listed forms have comparable efficacy or a proven safety profile in humans.
The availability of a specific form on the market is not also synonymous with its approval for medical use.
Pharmacokinetics of BPC-157
Pharmacokinetics describes the processes that occur from the moment a substance is introduced into the body until it is eliminated. It includes absorption, distribution, metabolism, and excretion.
In studies in rats and beagles, the behavior of BPC-157 in the body after experimental administration was evaluated [4].
Half-life and absorption period
In the animal models analyzed, the half-life of BPC-157 in the elimination phase was less than 30 minutes. This means that the concentration of the substance in the bloodstream decreased relatively quickly.
Linear pharmacokinetics was also observed within the range of doses studied. In simple terms, this means that the body's exposure to the substance changed proportionally to the administered amount.
After intramuscular administration, the maximum concentration of BPC-157 in the blood was reached after approximately 9 minutes.
In an experiment lasting seven days involving repeated administration, no significant changes in pharmacokinetic parameters were observed compared to a single administration of the same dose.
Bioavailability of BPC-157
Bioavailability determines the portion of the administered substance that reaches the general circulation in unchanged form.
In the study following intramuscular administration, the following values were obtained:
- Rats: approximately 14–19%.
- Beagle breeds: about 45–51%.
Differences between species indicate that pharmacokinetic results obtained in animals cannot be automatically transferred to humans.
Distribution and metabolism
In the BPC-157 experiments, higher concentrations were detected in various tissues of the body. Higher concentrations than in the blood were observed, among others, in the kidneys, liver, stomach wall, gall bladder, and spleen.
The study also analyzed peptide metabolism products. Among the detected metabolites was proline, one of the amino acids that make up proteins.
The liver and kidneys were primarily involved in the elimination processes [4].
The data described concern specific animal models and do not represent the full pharmacokinetic profile of BPC-157 in humans.
Stability of the BPC-157
The stability of a peptide means its ability to maintain its chemical structure under certain conditions.
In the case of BPC-157, resistance to hydrolysis, the action of enzymes, and the environment of gastric juice were studied [5].
Some experiments indicated relatively high stability of certain forms of this peptide. However, these results depended on the type of compound, the experimental conditions, and the analytical methods used.
Stability in aqueous solutions
The research materials described the solubility of BPC-157 in water with a pH close to neutral and in solutions of physiological salt.
It was also noted that it is resistant to certain acidic conditions.
However, solubility and chemical stability are not the same thing. A peptide may dissolve in a given environment while undergoing gradual chemical changes during storage.
Therefore, the assessment of stability requires consideration of time, temperature, pH, the composition of the solution, and the results of analytical tests.
Stability of the arginine salt of BPC-157
The studies compared the stability of different forms of BPC-157, including the arginine salt referred to as Arg-BPC.
In some tests, Arg-BPC showed greater stability at elevated temperatures, also under conditions involving 50°C [5].
Furthermore, greater resistance of this form to the gastric juice environment was observed compared to other forms of BPC-157 selected.
These results suggest that the type of counterion may affect the physicochemical properties of the peptide.
However, increased stability in an experiment should not be equated with proven clinical effectiveness.
Data regarding chemical resistance also do not allow for the determination of the appropriate storage period, storage conditions, or the safety of use of a particular product on their own.
BPC-157 octan salt and the gastric environment
In some materials, the stability of the BPC-157 octanoyl salt in an acidic environment was described to be lower than that of the arginine salt [5].
Under experimental conditions, the breakdown of a peptide can limit the amount of unchanged substance available for absorption.
On this basis, the researchers analyzed the importance of different chemical forms for potential oral administration.
However, this does not mean that acetic salt is only intended for injection or that arginine salt has been proven effective when administered orally in humans.
Appropriately designed pharmacokinetic, safety and clinical efficacy studies would be needed to reach such conclusions.
BPC-157 – dosage in studies and use in humans
Various experimental doses have been described in the literature regarding BPC-157, primarily those used in rats.
In one of the discussed examples, the oral dose was 10 µg/kg body weight. The source material also presents an approximate conversion to a human equivalent dose [6].
Such calculations are a tool used in preclinical analysis, not a method for determining safe dosages.
Differences between species include metabolism, physiology, bioavailability, and tissue sensitivity to the substance.
A reliable, approved dosing regimen for BPC-157 in humans has not been established. Data from animals should not be used to independently determine doses or the method of administration.
BPC-157 – potential mechanisms of action and results of studies
BPC-157 has been studied in many models of tissue damage and physiological disorders.
The mechanisms most frequently analyzed include modulation of signaling pathways, inflammatory responses, endothelial function of blood vessels, and processes related to tissue repair.
The following sections present the most important observations from preclinical studies.
BPC-157 and the central nervous system
In animal experiments, the effect of BPC-157 on the brain, spinal cord, and selected neurotransmitter systems was analyzed [7].
Stroke and cerebral ischemia
In studies in rats, the effect of BPC-157 on neuronal damage caused by cerebral ischemia was evaluated.
In some experiments, smaller damage to the nerve tissue was observed, as well as improvements in selected parameters related to memory, movement, and coordination [7, 8].
Changes in gene expression in the hippocampus, a brain structure involved in processes such as learning and memory formation, were also studied.
The results indicate a possible role of BPC-157 in the mechanisms of the nervous tissue's response to ischemia, but do not confirm its effectiveness in the treatment of stroke in humans.
Models of dopaminergic disorders and catalepsy
In other experiments, the effect of BPC-157 on the behavior of animals resembling some symptoms of neuropsychiatric disorders was evaluated.
Cataleptic paralysis involves a significant restriction of spontaneous movements and the maintenance of a specific body position.
The studies analyzed the interactions of BPC-157 with the nitric oxide system and substances affecting dopaminergic signaling [7].
The observed changes in animal behavior do not, however, indicate that BPC-157 is an effective treatment for schizophrenia or other psychiatric disorders.
Spinal cord injuries
In models of spinal cord compression and injury in rats, the effect of BPC-157 on nerve tissue regeneration and the return of motor function was studied.
In some of the experiments, improvements in selected neurological parameters were observed, including a reduction in tail motor dysfunction.
The inflammatory response, the functioning of blood vessels, and changes in damaged tissue were also analyzed [7, 9, 10].
These are preclinical results that require further evaluation before considering any medical applications.
BPC-157 and the GABA system
GABA, or gamma-aminobutyric acid, is one of the main inhibitory neurotransmitters in the central nervous system.
It participates in the regulation of neuronal excitability, muscle tension, and many processes related to behavior.
Animal studies have analyzed the effect of BPC-157 on disorders of the GABAergic signaling pathway, including changes associated with diazepam [7, 53].
In some models, a reduction in tolerance development or certain withdrawal symptoms have been observed.
Anti-seizure activity was also described in selected experiences.
However, it has not been determined whether these results are of clinical significance in humans.
BPC-157 and the musculoskeletal system
One of the areas most frequently studied is the effect of BPC-157 on the repair processes of tendons, ligaments, and muscles [11].
Muscles and ligaments
The tendons connect the muscles to the bones, while the ligaments stabilize the connections between the bones.
Due to the specific structure and limited blood supply, some damage to these structures heals relatively slowly.
In studies in rats with experimentally damaged Achilles tendons, changes were observed suggesting faster tissue repair and improved selected mechanical parameters [12].
Similar observations were described in models of damage to other tendons and ligaments [11, 13].
Different routes of administration were used in the experiments, but these comparisons do not allow the determination of an effective method of treating injuries in humans.
Damage to skeletal muscles
In experiments on rats, muscle regeneration after their mechanical cutting was also analyzed.
In one of the models, the healing process of the quadriceps muscle in the thigh was studied over 72 days.
More favorable results were observed in some histological and functional assessments in experimental groups receiving BPC-157 [14].
Muscle regeneration and corticosteroids
Corticosteroids can affect the repair processes of tissues.
Animal studies evaluated whether BPC-157 modifies the course of muscle regeneration under experimental conditions of impaired healing caused by these substances.
In some of the experiments, improvements in selected regeneration indicators were observed [15].
However, these results do not confirm that BPC-157 can prevent the adverse effects of corticosteroids in patients.
Possible mechanisms of BPC-157’s effects on skeletal muscle tissues
The literature describes several mechanisms that may be involved in the preclinical effects observed [11–17].
The FAK–pacsin pathway
FAK, or adhesion focal kinase, and paxillin are involved in the regulation of cell adhesion to the environment and their movement.
The studies analyzed whether BPC-157 affects this signaling pathway in muscle cells.
Changes in the activity of the FAK–paxlins pathway may be relevant for cell migration and the remodeling of damaged tissue.
Organization of collagen cells and fibers
The healing process requires the cooperation of various cell populations and the proper organization of the extracellular matrix.
Changes were observed in the cells involved in regeneration and the organization of collagen fibers in experiments with BPC-157.
Collagen is one of the basic structural components of tendons, ligaments, and skin.
Proteolytic processes
Proteolysis involves the breakdown of proteins by enzymes.
In certain experimental conditions, the possibility of BPC-157 influencing the processes of protein degradation in muscle tissues was analyzed.
The significance of these observations for muscle regeneration in humans remains uncertain.
Angiogenesis
Angiogenesis is the process of formation of new blood vessels.
It plays an important role in healing because it allows oxygen and nutrients to be delivered to the regenerating tissue.
Some studies suggested that BPC-157 may affect factors related to blood vessel formation.
Growth hormone receptor
In cell studies, the expression of the growth hormone receptor in muscle fibroblasts was also analyzed.
The observed changes may indicate interactions with mechanisms regulating growth and tissue remodeling [17].
However, they do not provide evidence of the effectiveness of BPC-157 in the treatment of musculoskeletal injuries in humans.
BPC-157 and brain damage
Traumatic brain injuries
In studies in mice, the effect of BPC-157 on the consequences of experimental brain injuries was analyzed.
Changes were observed regarding the extent of damage, bleeding, swelling, and selected neurological parameters.
In some animal groups, more favorable results were obtained regarding neurological status and survival [18, 19].
Brain swelling and vascular disorders
In subsequent models, situations were studied in which vessel obstruction led to circulatory disorders and damage to the brain and other organs.
In some of the experiments with BPC-157, there was a reduction in brain swelling, changes in intracranial pressure, and improvements in selected vascular parameters [20–22].
These results apply to specific animal models and do not confirm efficacy in the treatment of brain injuries in humans.
BPC-157 and the cardiovascular system
In preclinical studies, the effect of BPC-157 on the heart, blood vessels, and blood flow disorders was analyzed.
Heart failure
In animal models of heart failure, changes related to heart enlargement, damage to the heart muscle, and blood stagnation were evaluated.
In some experiments, a reduction in some of these changes was observed after the use of BPC-157 [23].
The studies also included damage caused by certain chemical substances or physiological disturbances.
Myocardial infarction
In models of heart attack in rats, the effect of BPC-157 on myocardial damage and functional parameters was studied.
Smaller increases in some histological changes and heart rhythm disorders were described [24].
However, this does not mean that BPC-157 is an effective treatment for heart attacks in humans.
Thrombosis and blood clotting
In experiments concerning vessel obstruction, the effect of BPC-157 on arterial and venous thrombosis was evaluated.
Researchers analyzed, among other things, the function of blood platelets, the state of the endothelium, and the activity of the nitric oxide system [25].
In some models, a reduction in clotting changes was observed.
Blood pressure disorders
In studies in rats, severe hemodynamic disorders were analyzed, including hypertension in specific areas of the venous system and a reduction in arterial pressure.
In selected trials, BPC-157 was associated with partial normalization of some cardiovascular parameters [26, 27].
It has not been determined whether similar mechanisms occur in humans.
Heart rhythm disorders
BPC-157 has also been studied in models of arrhythmia associated with heart damage or the effects of certain substances.
In some of the experiments, a reduction in the frequency or severity of certain rhythm disorders was observed.
One of the mechanisms analyzed was the interaction with the nitric oxide system [28].
Bleeding and thrombocytopenia
In studies in rats with experimental bleeding, the time of blood loss and platelet function were analyzed.
In some groups receiving BPC-157, a shorter bleeding time was observed despite the use of anticoagulants [29].
The syndrome of intra-abdominal distention
The condition of intra-abdominal pressure develops when excessive pressure in the abdominal cavity disrupts the functioning of the organs.
In an experimental model of this condition in rats, the effects of BPC-157 on circulation, edema, and organ damage were studied.
In part of the studies, improvements in selected hemodynamic parameters and a reduction in tissue changes were observed [30].
Vascular obstruction and organ dysfunction
In models for closing large vessels, the possibility of activating the lateral circulation was studied.
Lateral circulation allows blood to flow through alternative routes, bypassing the obstructed section of the vessel.
Changes suggestive of activation of such mechanisms and a reduction of some consequences of ischemia were observed in experiments with BPC-157 [31].
These are experimental observations, and not a confirmed method of treating thrombosis or organ dysfunction.
BPC-157 and behavior and neurotransmitters
Models of depression
The potential effect of BPC-157 on stress-related behaviors was analyzed in depression models in rats.
Among other things, the forced swimming test and the model of chronic, unpredictable stress were used [32].
In some of the experiments, a reduction in the animals’ time of immobility was observed.
Similar indicators are used in studies of antidepressants, but their change does not necessarily mean that the antidepressant effect in humans has been confirmed.
Serotonin system
The serotonin syndrome is a potentially dangerous condition associated with excessive activity of the serotoninergic signaling system.
In studies in rats, the effect of BPC-157 on experimentally induced serotoninergic disorders was analyzed.
In some models, a reduction of certain symptoms was observed, including those related to the activation of 5-HT2A receptors [33].
Models of fear
In behavioral studies in rats, the effects of BPC-157 and diazepam on anxiety-related behaviors were compared.
In some experiments, animals receiving BPC-157 showed a lesser intensity of certain defense responses [34].
However, the mechanisms of the observed changes were not identical to the action of diazepam.
Synthesis of serotonin
Serotonin is involved in regulating many functions of the nervous system, including mood, sleep, and information processing.
In studies in rats, the effect of BPC-157 on the synthesis of serotonin in different brain structures was evaluated.
Changes were observed in areas involving the hillock, hippocampus, hypothalamus, the amygdala, and selected olfactory structures [35].
The significance of these changes for human health remains unclear.
BPC-157 in studies on the toxicity of drugs and chemical substances
A large group of preclinical studies concerns the effect of BPC-157 on damage caused by drugs and other substances.
The results of these experiments do not mean that BPC-157 is an antidote approved for use in humans.
Toxicity of glycoside herbicides
Glycoside derivatives such as digoxin can cause serious heart rhythm disturbances in case of poisoning.
In studies in rats, the effect of BPC-157 on arrhythmias caused by substances in this group was analyzed.
In some experiments, a reduction in conduction and heart rhythm disorders was observed [36].
Hyperkalemia
Hyperkalemia means an excessive concentration of potassium in the blood.
It can lead to dangerous electrical conduction disorders in the heart.
In animal models, it was evaluated whether BPC-157 affects the consequences of experimentally induced hyperkalemia.
In part of the studies, a reduction in the severity of arrhythmias and selected physiological disorders was observed [7].
The action of succinylcholine
Succinylcholine is a muscle relaxant used in certain anesthesia procedures.
In animal studies, its adverse effects were analyzed, including hyperkalemia and heart rhythm disorders.
In some models, BPC-157 limited the selected effects of succinylcholine [37].
Hypokalemia caused by furosemide
Hypokalemia means too low a concentration of potassium in the blood.
In experiments using furosemide, electrolyte disorders and associated arrhythmias were studied.
In some of the experiments, a smaller increase in heart rhythm disorders was observed after the use of BPC-157 [7].
The toxicity of lidocaine
Lidocaine is a local anesthetic that, when overused, can cause seizures and cardiovascular disorders.
In animal studies, the effect of BPC-157 on selected toxic effects of lidocaine was analyzed [7].
Prolongation of the QTc interval
The QTc interval is an electrocardiographic parameter used to assess repolarization of the heart cells.
Some medications can cause it to prolong and increase the risk of dangerous arrhythmias.
In studies in rats, the effect of BPC-157 on the prolongation of the QTc interval caused by certain antipsychotic and prokinetic drugs was evaluated.
In some of the experiments, a reduction in these changes was observed [38].
Liver damage caused by radiation
In studies in mice, the effect of BPC-157 on liver damage caused by radiation exposure was analyzed.
In some experiments, a smaller increase in tissue changes and disorders related to lipid accumulation was observed [39].
Toxicity of non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs, or NSAIDs, can cause damage to the mucous membrane of the gastrointestinal tract, and in certain situations, also to other organs.
Animal studies evaluated the effect of BPC-157 on the changes caused by drugs in this group.
In some models, a reduction in damage to the stomach, intestines, and liver was observed [40].
Lithium toxicity
Lithium is used to treat selected mental disorders, but excessive levels can lead to poisoning.
In animal models, the effect of BPC-157 on organ and vascular disorders caused by high exposure to lit was analyzed.
In some of the experiments, a reduction in some of the toxic effects was observed [41].
Liver damage associated with alcohol
In studies in rats chronically exposed to alcohol, the effect of BPC-157 on liver changes and pressure in the portal venous system was evaluated.
In some of the experiments, a smaller increase in histological changes and circulatory disorders was observed [42].
Cardiotoxicity of bupivacaine
Bupivacaine is a local anesthetic that, when overexposed, can cause severe heart dysfunction.
In experiments on rats, the effect of BPC-157 on selected toxic effects of bupivacaine was investigated.
In some models, a reduction in cardiovascular damage and an improvement in survival were observed [43].
High levels of Magnesium
Hypermagnesemia can lead, among other things, to muscle weakness and neurological and circulatory disorders.
In studies in rats, the effects of BPC-157 on the consequences of experimentally induced magnesium overload were evaluated.
In some of the experiments, a limitation of selected disorders was observed [44].
Overdose of paracetamol
Overdose of paracetamol can lead to severe liver damage.
Animal studies analyzed the effects of BPC-157 on the consequences of toxic exposure, including liver damage, brain damage, and seizures.
In some models, a smaller intensification of these changes and an improvement in selected biochemical parameters were observed [45].
This does not constitute a basis for the use of BPC-157 in paracetamol poisoning in humans.
Toxicity of pain medications
In other studies, the damage to the digestive tract, the liver, and the nervous system associated with the effects of certain painkillers was evaluated.
In some of the BPC-157 experiments, there was a reduction in tissue changes and some behavioral disorders in the animals [46].
Overdose of insulin
Excessive amounts of insulin can cause severe hypoglycemia, a dangerous drop in blood glucose levels.
In studies in rats, the effect of BPC-157 on the consequences of experimental overdose with insulin was analyzed.
In some of the experiments, a reduction in tremors, changes in the liver, brain damage, and other organ disorders were observed [47].
Prolonged exposure to ibuprofen
Changes in the gastrointestinal tract, liver, and brain were assessed in models of prolonged ibuprofen action.
In some experiments, a smaller severity of damage was observed in animals receiving BPC-157 [48].
Adverse behavioral disorders associated with amphetamine
In studies in rats, the effect of BPC-157 on behavioral changes caused by chronic exposure to amphetamine was analyzed.
In some of the experiments, a reduction in certain behaviors associated with excessive stimulation was observed [49].
This does not confirm the efficacy of BPC-157 in the treatment of addiction or the consequences of the use of amphetamine in humans.
BPC-157 and the digestive tract
The gastrointestinal tract is one of the areas of action of BPC-157 that have been studied the earliest.
The experiments included lesions of the mucous membrane, inflammatory conditions, motor disorders, and processes of tissue healing.
Non-inflammatory bowel diseases and models of demyelination
In animal studies, the effect of BPC-157 on experimental colitis was analyzed.
In some of the experiments, a reduction in inflammatory changes and an improvement in selected healing indicators were observed.
In the same research area, models of nervous system damage resembling specific elements of demyelination processes were also evaluated [50].
This does not mean proven efficacy in the treatment of non-inflammatory bowel diseases or multiple sclerosis in humans.
Small intestine team
The small intestine develops when the length of the active small intestine is insufficient for proper absorption of nutrients.
In studies in rats, the effect of BPC-157 on the process of adaptation of the remaining part of the intestine was evaluated.
In some groups, an increase in body weight and more favorable structural changes of the intestine were observed [51].
Damage to the optic nerve
The colon is the initial section of the large intestine.
In models of its damage, the effect of BPC-157 on healing and vascular processes was analyzed.
In some of the experiments, changes were observed that suggested the involvement of angiogenesis in the repair response [52].
Intestinal-brain axis
The enteric-brain axis involves bidirectional communication between the digestive tract and the central nervous system.
Among others, the nervous system, hormones, immune mediators, and the gut microbiota participate in it.
The literature has analyzed the possibility of the influence of BPC-157 on selected elements of this communication [53].
The observations come mainly from animal models and do not yet allow for determining the clinical significance of these interactions.
Permeability of the intestinal barrier
The intestinal barrier limits the penetration of undesirable substances from the intestinal lumen into the tissues and circulation.
The studies analyzed the effect of BPC-157 on increased intestinal permeability caused by specific factors, including NLPZ.
In some models, a reduction in epithelial damage and changes in permeability were observed [54].
Intestinal obstructions and injuries
A flow is an abnormal connection between organs or between an organ and the surface of the body.
Animal experiments evaluated the effect of BPC-157 on the healing of various types of wounds and injuries of the digestive tract.
In some models, faster organization of reparative tissue and closure of damaged areas were observed [55].
Ulcerative gastritis
In studies in rats with experimentally induced gastric ulcers, the effect of BPC-157 on the surface of the lesions and the course of healing was analyzed.
In some experiments, a reduction in the surface area of the lesions was observed, as well as more favorable histological evaluation results.
In certain models, inhibition of the development of ulcerous changes was described in the range of 45.7% to 65.6% [56].
These values refer to specific experimental conditions and do not represent clinical efficacy in humans.
Ulcer of the duodenum
The duodenum is the first section of the small intestine.
In studies in rats, the effect of BPC-157 was evaluated in models of pancreatic damage, also after certain surgical procedures.
In some of the experiments, the protective effects were observed to persist under conditions where the activity of some other substances was limited [57].
Damage to the large intestine
In models of chronic changes in the large intestine, the effect of BPC-157 was compared with that of selected substances used in anti-ulcerative experiments.
In some groups, a smaller degree of damage was observed, also during subsequent observation [58].
Damage to the lungs and stomach
In studies in rats, the co-occurrence of stomach and lung damage was analyzed.
In some of the experiments with BPC-157 and other studied substances, a reduction in certain tissue changes was observed [59, 60].
Stomach inflammation and digestive disorders
In experimental models of chronic inflammation of the esophagus, the function of the lower esophageal sphincter and the diaphragm was studied.
In some experiments, changes in the pressure of these animals were observed, as well as a smaller increase in inflammatory changes.
The studies also compared the results with the effects of ranitidine [61, 62].
Cytoprotection of the intestinal cells
In studies concerning the enteric nervous system, the effect of BPC-157 on neurons and glial cells was analyzed.
In some of the experiments, changes in cell viability, the motility of the digestive tract, and the release of serotonin were observed.
At the same time, changes in some of the contraction responses to serotonin and noradrenaline were not observed [63, 64].
Rectal-bowal flow
Rectal-urethral obstruction is an abnormal connection between the rectum and the urethra.
Studies in rats evaluated the effect of BPC-157 on the healing of this type of injury.
In some of the experiments, the closure of the ducts was observed, the tissue structure improved, and some complications were reduced [65].
Protection of the stomach and duodenum
In other studies, the effect of BPC-157 on changes in the mucous membrane of the stomach and duodenum was analyzed.
In some models, a reduction in damage and inflammatory responses was observed [66].
Damage to the stomach caused by alcohol
In models of acute alcohol exposure, not only changes in the stomach were assessed, but also vascular and organ disorders.
In some of the BPC-157 experiments, a reduction in selected tissue changes and circulatory disorders was observed [67].
Circumventive-skin flow
The perianal canal is an abnormal connection between the large intestine and the skin.
In studies in rats, the process of closing such fistulas was observed, as well as changes related to the regeneration of the intestinal wall and skin.
In some experiments, the contribution of the nitric oxide system was also analyzed [68].
BPC-157 and the liver
Damage to the liver caused by alcohol
In studies in rats subjected to chronic exposure to alcohol, histological changes in the liver and portal pressure were analyzed.
In one of the models, the exhibition lasted three months.
In the groups receiving BPC-157, less severe exacerbation of some cellular changes, lipid accumulation, and circulatory disorders were observed [69].
The Budda-Chiariego team
The Budda-Chiarie syndrome includes disorders of venous blood outflow from the liver.
In an experimental model of this team in rats, the effect of BPC-157 on peripheral circulation, thrombosis, and organ function was evaluated.
In part of the studies, an improvement in blood flow was observed and the occurrence of selected complications of vascular obstruction was reduced [70].
Liver fibrosis and portal hypertension
In studies in rats with tethered bile ducts, changes leading to liver damage were analyzed.
In some studies, BPC-157 was associated with improvements in selected biochemical and histological parameters and a reduction in the severity of jaundice and dehydration [71, 72].
Damage to the digestive tract and the liver
In subsequent studies, the possibility of the involvement of the adrenergic and dopaminergic systems in the observed protective effects was analyzed.
These systems are involved in the regulation of many body functions, including blood vessel tension and the activity of the nervous system [73].
BPC-157 and the eye organ
Glaucoma
Migraine encompasses a group of diseases that lead to damage to the optic nerve.
In studies in rats with experimentally induced increases in intraocular pressure, the effect of BPC-157 on pressure and eye structure was analyzed.
In some of the experiments, normalization of pressure and a reduction of certain changes in the optic nerve and retinal vessels were observed [74].
Damage to the corneal epithelium
The tear duct is a transparent structure located in the front part of the eye.
In models of corneal damage in rats, the rate of healing was evaluated after the use of BPC-157.
In some groups, complete closure of experimental lesions was observed within 40–48 hours [75].
Eye blood vessel insufficiency
Retinal ischemia develops as a result of insufficient blood flow to its tissues.
In animal studies, the effect of BPC-157 on the structure of the retina and its vessels was analyzed after an experimental disruption of blood flow.
In some of the experiments, improvements in selected morphological parameters were observed [76].
Scarring and corneal transparency
In models of traumatic corneal damage in rats, healing, vessel formation, and tissue transparency were evaluated.
In some experiments, closure of lesions was observed within 72–96 hours and changes related to the restoration of corneal structure were observed [77].
These results do not confirm the efficacy or safety of BPC-157 in eye diseases in humans.
BPC-157 and pain and inflammation
Knee pain and joint diseases
In a small study involving people with knee pain, the results were evaluated after administration of BPC-157 by infusion.
The authors described an improvement in the symptoms in some participants [78].
However, due to the methodological limitations of this type of observation, they cannot be considered evidence of the effectiveness of the treatment. They also do not confirm tissue regeneration or a reduction in the need for surgery.
Pain after surgical incision
In studies in rats with experimental surgical incisions, the pain responses following the administration of BPC-157 were analyzed.
At certain time points, an increase in the threshold of response to pain stimuli was observed [79].
Inflammation of the joints and damage to the digestive tract
In models of chronic arthritis in rats, the effect of BPC-157 on inflammatory changes and damage to the gastrointestinal tract caused by NSAIDs was evaluated.
In some of the experiments, a reduction in certain changes in the joints, stomach and intestines was observed.
The results of the observations conducted after two weeks and over a longer period, lasting up to a year, were also described [80].
Other studied properties of BPC-157
Puncture-peritoneal drainage
The urethral-urethral flow is an abnormal connection between the urethra and the bladder.
Studies in rats analyzed the effect of BPC-157 on the healing process of these types of injuries.
In some of the experiments, a reduction in urinary leakage was observed, changes related to tissue repair, and a reduction in the severity of some complications [81].
Wound healing and collagen organization
In preclinical studies, the effect of BPC-157 on the formation of the seed and the organization of collagen fibers was analyzed.
A granulation is a tissue that forms during wound healing.
Changes in the expression of the EGR-1 gene, which is involved in the regulation of cellular processes related to tissue repair, were observed in some models [82].
Inflammation of the bladder
In studies in rats, hemorrhagic cystitis caused by cyclophosphamide was analyzed.
In some of the experiments, a reduction in hemorrhagic changes and an improvement in selected functional parameters of the bladder were observed after the administration of BPC-157 [83].
Acute pancreatitis
In experimental models of acute pancreatitis, vascular disorders, inflammation, and damage to other organs were assessed.
In some studies, BPC-157 was associated with a reduction in some tissue changes and circulatory disorders [84].
The concomitant disorders of the esophageal function and its sphincters were also analyzed.
The results are from preclinical models and do not constitute a basis for the use of BPC-157 in the treatment of pancreatitis in humans.
What do the current studies on BPC-157 reveal?
Research on BPC-157 covers a wide range of biological processes, including tissue regeneration, inflammatory response, blood vessel function, and cellular protection mechanisms.
Changes were observed in many animal models that suggest the biological activity of the peptide.
At the same time, the scope of these observations should not be equated with the number of confirmed clinical applications.
Most of the experiments described were conducted on rats or mice. The studies differed in terms of the models used, the methods of administration, the parameters evaluated, and the duration of observation.
The results obtained in animals do not allow for the self-determination of the efficacy, safety, dosage or long-term consequences of the use of BPC-157 in humans.
Summary
BPC-157 is a synthetic pentadecapeptide that has attracted the interest of researchers due to its observed activity in various preclinical models.
The experiments included, among other things, damage to muscles, tendons, ligaments, the digestive tract, the nervous system, and blood vessels.
Its pharmacokinetics, chemical stability, and possible interactions with inflammatory processes, angiogenesis, and signaling pathways were also studied.
Despite numerous experimental observations, there are still insufficient high-quality clinical data that would confirm the safety and efficacy of BPC-157 in the treatment of the listed diseases in humans.
Further studies should include a more thorough evaluation of the mechanisms of action, toxicity, and pharmacokinetics in humans, as well as the results of appropriately controlled clinical trials.
Medical disclaimer
The article is purely educational and informational in nature. The information presented primarily concerns laboratory studies and animal experiments, the results of which cannot be directly transferred to humans.
BPC-157 is an experimental substance and is not a licensed drug for the treatment of the described conditions. Its safety, efficacy, and appropriate dosage in humans have not been sufficiently established.
The content does not constitute medical advice, recommendations for the use of BPC-157, or instructions for self-treatment. In case of health problems, use diagnostic and therapeutic methods with proven safety and effectiveness and consult a qualified health care professional.
References
- Sikiric P. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology, 7(1), 1–14. https://doi.org/10.1007/s10787-999-0022-z https://pubmed.ncbi.nlm.nih.gov/17657443/
- Sikiric P. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology, 7(1), 1–14. https://doi.org/10.1007/s10787-999-0022-z https://pubmed.ncbi.nlm.nih.gov/17657443/
- https://examine.com/supplements/bpc-157/
- He, L., Feng, D., Guo, H., Zhou, Y., Li, Z., Zhang, K., Zhang, W., Wang, S., Wang, Z., Hao, Q., Zhang, C., Gao, Y., Gu, J., Zhang, Y., Li, W., & Li, M. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in pharmacology, 13, 1026182. https://doi.org/10.3389/fphar.2022.1026182 https://pubmed.ncbi.nlm.nih.gov/36588717/
- https://patents.google.com/patent/WO2014142764A1/en
- https://examine.com/supplements/bpc-157/
- Perovic, D., Kolenc, D., Bilic, V., Somun, N., Drmic, D., Elabjer, E., Buljat, G., Seiwerth, S., & Sikiric, P. (2019). Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of orthopaedic surgery and research, 14(1), 199. https://doi.org/10.1186/s13018-019-1242-6 https://pubmed.ncbi.nlm.nih.gov/31266512/
- Vukojević, J., Vrdoljak, B., Malekinušić, D., Siroglavić, M., Milavić, M., Kolenc, D., Boban Blagaić, A., Batelja, L., Drmić, D., Seiverth, S., & Sikirić, P. (2020). The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain and behaviour, 10(8), e01726. https://doi.org/10.1002/brb3.1726 https://pubmed.ncbi.nlm.nih.gov/32558293/
- Perovic, D., Milavic, M., Dokuzovic, S., Krezic, I., Gojkovic, S., Vranes, H., Bebek, I., Bilic, V., Somun, N., Brizic, I., Skorak, I., Hriberski, K., Sikiric, S., Lovric, E., Strbe, S., Kubat, M., Boban Blagaic, A., Skrtic, A., Seiwerth, S., & Sikiric, P. (2022). Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy. Current issues in molecular biology, 44(5), 1901-1927. https://doi.org/10.3390/cimb44050130 https://pubmed.ncbi.nlm.nih.gov/35678659/
- Vukojevic, J., Milavić, M., Perović, D., Ilić, S., Čilić, A. Z., Đuran, N., Štrbe, S., Zoričić, Z., Filipčić, I., Brečić, P., Seiverth, S., & Sikirić, P. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural regeneration research, 17(3), 482-487. https://doi.org/10.4103/1673-5374.320969 https://pubmed.ncbi.nlm.nih.gov/34380875/
- Gwyer, Daniel; Wragg, Nicholas M.; Wilson, Samantha L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, (), –. doi:10.1007/s00441-019-03016-8 https://sci-hub.mksa.top/10.1007/s00441-019-03016-8
- Krivic, A., Majerovic, M., Jelic, I., Seiwerth, S., & Sikiric, P. (2008). Modulation of early functional recovery of the Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflammation research : official journal of the European Histamine Research Society … [et al.], 57(5), 205–210. https://doi.org/10.1007/s00011-007-7056-8 https://pubmed.ncbi.nlm.nih.gov/18594781/
- Cerovecki, T., Bojanic, I., Brcic, L., Radic, B., Vukoja, I., Seiwerth, S., & Sikiric, P. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 28(9), 1155–1161. https://doi.org/10.1002/jor.21107 https://pubmed.ncbi.nlm.nih.gov/20225319/
- Staresinic, M., Petrovic, I., Novinscak, T., Jukic, I., Pevec, D., Suknaic, S., Kokic, N., Batelja, L., Brcic, L., Boban-Blagaic, A., Zoric, Z., Ivanovic, D., Ajduk, M., Sebecic, B., Patrlj, L., Sosa, T., Buljat, G., Anic, T., Seiwerth, S., & Sikiric, P. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 24(5), 1109–1117. https://doi.org/10.1002/jor.20089 https://pubmed.ncbi.nlm.nih.gov/16609979/
- Pevec, D., Novinscak, T., Brcic, L., Sipos, K., Jukic, I., Staresinic, M., Mise, S., Brcic, I., Kolenc, D., Klicek, R., Banic, T., Sever, M., Kocijan, A., Berkopic, L., Radic, B., Buljat, G., Anic, T., Zoricic, I., Bojanic, I., Seiwerth, S., … Sikiric, P. (2010). Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical science monitor : international medical journal of experimental and clinical research, 16(3), BR81–BR88. https://pubmed.ncbi.nlm.nih.gov/20190676/
- Japjec, M., Horvat Pavlov, K., Petrovic, A., Staresinic, M., Sebecic, B., Buljan, M., Vranes, H., Giljanovic, A., Drmic, D., Japjec, M., Prtoric, A., Lovric, E., Batelja Vuletic, L., Dobric, I., Boban Blagaic, A., Skrtic, A., Seiwerth, S., & Predrag, S. (2021). Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines, 9(11), 1547. https://doi.org/10.3390/biomedicines9111547 https://pubmed.ncbi.nlm.nih.gov/34829776/
- Chang, C. H., Tsai, W. C., Hsu, Y. H., & Pang, J. H. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (Basel, Switzerland), 19(11), 19066–19077.https://doi.org/10.3390/molecules191119066 https://pubmed.ncbi.nlm.nih.gov/25415472/
- Tudor, M., Jandric, I., Marovic, A., Gjurasin, M., Perovic, D., Radic, B., Blagaic, A. B., Kolenc, D., Brcic, L., Zarkovic, K., Seiwerth, S., & Sikiric, P. (2010). Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory peptides, 160(1-3), 26-32. https://doi.org/10.1016/j.regpep.2009.11.012 https://pubmed.ncbi.nlm.nih.gov/19931318/
- Gojkovic, S., Krezic, I., Vranes, H., Zizek, H., Drmic, D., Horvat Pavlov, K., Petrovic, A., Batelja Vuletic, L., Milavic, M., Sikiric, S., Stilinovic, I., Samara, M., Knezevic, M., Barisic, I., Sjekavica, I., Lovric, E., Skrtic, A., Seiwerth, S., & Sikiric, P. (2021). BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment. Biomedicines, 9(7), 744. https://doi.org/10.3390/biomedicines9070744 https://pubmed.ncbi.nlm.nih.gov/34203464/
- Ilic, S., Drmic, D., Zarkovic, K., Kolenc, D., Coric, M., Brcic, L., Klicek, R., Radic, B., Sever, M., Djuzel, V., Ivica, M., Boban Blagaic, A., Zoricic, Z., Anic, T., Zoricic, I., Djidic, S., Seiwerth, S., & Sikiric, P. (2010). Zwiększona toksyczność dla wątroby paracetamolu wywołuję generalizowaną konwulsję oraz szkody w obrębie ośrodkowego układu nerwowościu w myszach. Przeciwwskazanie stosowania stałego peptydu pentadekaprylowego w jamie ustnej BPC 157 (PL 14736). Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 61(2), 241–250. https://pubmed.ncbi.nlm.nih.gov/20436226/
- Ilic, S., Brcic, I., Mester, M., Filipovic, M., Sever, M., Barisic, I., Radic, B., Zoricic, Z., Bilic, V., Berkopic, L., Brcic, L., Kolenc, D., Romic, Z., Pazanin, L., Seiwerth, S., & Sikiric, P. (2009). Overdose of insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 60 Suppl 7, 107-114. https://pubmed.ncbi.nlm.nih.gov/20388953/
- Drmic, D., Kolenc, D., Ilic, S., Bauk, L., Sever, M., Zenko Sever, A., Luetic, K., Suran, J., Seiwerth, S., & Sikiric, P. (2017). Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World journal of gastroenterology, 23(29), 5304-5312. https://doi.org/10.3748/wjg.v23.i29.5304 https://pubmed.ncbi.nlm.nih.gov/28839430/
- Sikiric, P., Udovicic, M., Barisic, I., Balenovic, D., Zivanovic Posilovic, G., Strinic, D., Uzun, S., Sikiric, S., Krezic, I., Zizek, H., Yago, H., Gojkovic, S., Smoday, I. M., Kalogjera, L., Vranes, H., Sola, M., Strbe, S., Koprivanac, A., Premuzic Mestrovic, I., Mestrovic, T., … Seiwerth, S. (2022). Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines, 10(11), 2696. https://doi.org/10.3390/biomedicines10112696 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687817/
- Barisic, I., Balenovic, D., Udovicic, M., Bardak, D., Strinic, D., Vlainić, J., Vranes, H., Smoday, I. M., Krezic, I., Milavic, M., Sikiric, S., Uzun, S., Zivanovic Posilovic, G., Strbe, S., Vukoja, I., Lovric, E., Lozic, M., Sever, M., Lovric Bencic, M., Boban Blagaic, A., … Sikiric, P. (2022). Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. Biomedicines, 10(2), 265. https://doi.org/10.3390/biomedicines10020265 https://pubmed.ncbi.nlm.nih.gov/35203478/
- Knezevic, M., Gojkovic, S., Krezic, I., Zizek, H., Malekinusic, D., Vrdoljak, B., Knezevic, T., Vranes, H., Drmic, D., Staroveski, M., Djuzel, A., Rajkovic, Z., Kolak, T., Lovric, E., Milavic, M., Sikiric, S., Tvrdeic, A., Patrlj, L., Strbe, S., Sola, M., … Sikiric, P. (2021). Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157. Biomedicines, 9(7), 792. https://doi.org/10.3390/biomedicines9070792 https://pubmed.ncbi.nlm.nih.gov/34356860/
- Udovicic, M., Sever, M., Kavur, L., Loncaric, K., Barisic, I., Balenovic, D., Zivanovic Posilovic, G., Strinic, D., Uzun, S., Batelja Vuletic, L., Sikiric, S., Skrtic, A., Drmic, D., Boban Blagaic, A., Lovric Bencic, M., Seiwerth, S., & Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal. Biomedicines, 9(7), 822. https://doi.org/10.3390/biomedicines9070822 https://pubmed.ncbi.nlm.nih.gov/34356886/
- Knezevic, M., Gojkovic, S., Krezic, I., Zizek, H., Malekinusic, D., Vrdoljak, B., Vranes, H., Knezevic, T., Barisic, I., Horvat Pavlov, K., Drmic, D., Staroveski, M., Djuzel, A., Rajkovic, Z., Kolak, T., Kocman, I., Lovric, E., Milavic, M., Sikiric, S., Tvrdeic, A., … Sikiric, P. (2021). Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines, 9(6), 609. https://doi.org/10.3390/biomedicines9060609 https://pubmed.ncbi.nlm.nih.gov/34073625/
- Balenovic, D., Bencic, M. L., Udovicic, M., Simonji, K., Hanzevacki, J. S., Barisic, I., Kranjcevic, S., Prkacin, I., Coric, V., Brcic, L., Coric, M., Brcic, I., Borovic, S., Radic, B., Drmic, D., Vrcic, H., Seiwerth, S., & Sikiric, P. (2009). Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regulatory peptides, 156(1-3), 83–89. https://doi.org/10.1016/j.regpep.2009.05.008 https://pubmed.ncbi.nlm.nih.gov/19465062/
- Stupnisek, M., Kokot, A., Drmic, D., Hrelec Patrlj, M., Zenko Sever, A., Kolenc, D., Radic, B., Suran, J., Bojic, D., Vcev, A., Seiwerth, S., & Sikiric, P. (2015). Pentadecapeptide BPC 157 reduces bleeding and thrombocytopenia after amputation in rats treated with heparin, warfarin, L-NAME and L-arginine. PloS one, 10(4), e0123454. https://doi.org/10.1371/journal.pone.0123454 https://pubmed.ncbi.nlm.nih.gov/25897838/
- Tepes, M., Gojkovic, S., Krezic, I., Zizek, H., Vranes, H., Madzar, Z., Santak, G., Batelja, L., Milavic, M., Sikiric, S., Kocman, I., Simonji, K., Samara, M., Knezevic, M., Barisic, I., Lovric, E., Strbe, S., Kokot, A., Sjekavica, I., Kolak, T., … Sikiric, P. (2021). Stabilna terapija gastričnim pentadekapeptidom BPC 157 za primarni abdominalni kompartmentalni sindrom u štakora. Frontiers in pharmacology, 12, 718147. https://doi.org/10.3389/fphar.2021.718147 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710746/
- Knezevic, M., Gojkovic, S., Krezic, I., Zizek, H., Malekinusic, D., Vrdoljak, B., Vranes, H., Knezevic, T., Barisic, I., Horvat Pavlov, K., Drmic, D., Staroveski, M., Djuzel, A., Rajkovic, Z., Kolak, T., Kocman, I., Lovric, E., Milavic, M., Sikiric, S., Tvrdeic, A., … Sikiric, P. (2021). Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines, 9(6), 609. https://doi.org/10.3390/biomedicines9060609 https://pubmed.ncbi.nlm.nih.gov/34073625/
- Sikiric, P., Separovic, J., Buljat, G., Anic, T., Stancic-Rokotov, D., Mikus, D., Marovic, A., Prkacin, I., Duplancic, B., Zoricic, I., Aralica, G., Lovric-Bencic, M., Ziger, T., Perovic, D., Rotkvic, I., Mise, S., Hanzevacki, M., Hahn, V., Seiwerth, S., Turkovic, B., … Rucman, R. (2000). The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic unpredictable stress in rats. A comparison with antidepressants. Journal of physiology, Paris, 94(2), 99-104. https://doi.org/10.1016/s0928-4257(00)00148-0 https://pubmed.ncbi.nlm.nih.gov/10791689/
- Boban Blagaic, A., Blagaic, V., Mirt, M., Jelovac, N., Dodig, G., Rucman, R., Petek, M., Turkovic, B., Anic, T., Dubovecak, M., Staresinic, M., Seiwerth, S., & Sikiric, P. (2005). Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. European journal of pharmacology, 512(2-3), 173–179. https://doi.org/10.1016/j.ejphar.2005.02.033 https://pubmed.ncbi.nlm.nih.gov/15840402/
- Sikiric, P., Jelovac, N., Jelovac-Gjeldum, A., Dodig, G., Staresinic, M., Anic, T., Zoricic, I., Ferovic, D., Aralica, G., Buljat, G., Prkacin, I., Lovric-Bencic, M., Separovic, J., Seiwerth, S., Rucman, R., Petek, M., Turkovic, B., & Ziger, T. (2001). Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. Acta pharmacologica Sinica, 22(3), 225-230. https://pubmed.ncbi.nlm.nih.gov/11742568/
- Tohyama, Y., Sikirić, P., & Diksic, M. (2004). Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life sciences, 76(3), 345-357. https://doi.org/10.1016/j.lfs.2004.08.010 https://pubmed.ncbi.nlm.nih.gov/15531385/
- Balenovic, D., Bencic, M. L., Udovicic, M., Simonji, K., Hanzevacki, J. S., Barisic, I., Kranjcevic, S., Prkacin, I., Coric, V., Brcic, L., Coric, M., Brcic, I., Borovic, S., Radic, B., Drmic, D., Vrcic, H., Seiwerth, S., & Sikiric, P. (2009). Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regulatory peptides, 156(1-3), 83–89. https://doi.org/10.1016/j.regpep.2009.05.008 https://pubmed.ncbi.nlm.nih.gov/19465062/
- Stambolija, V., Stambolija, T. P., Holjevac, J. K., Murselovic, T., Radonic, J., Duzel, V., Duplancic, B., Uzun, S., Zivanovic-Posilovic, G., Kolenc, D., Drmic, D., Romic, Z., Seiwerth, S., & Sikiric, P. (2016). BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. European journal of pharmacology, 781, 83-91. https://doi.org/10.1016/j.ejphar.2016.04.004 https://pubmed.ncbi.nlm.nih.gov/27060013/
- Strinic, D., Belosic Halle, Z., Luetic, K., Nedic, A., Petrovic, I., Sucic, M., Zivanovic Posilovic, G., Balenovic, D., Strbe, S., Udovicic, M., Drmic, D., Stupnisek, M., Lovric Bencic, M., Seiwerth, S., & Sikiric, P. (2017). BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life sciences, 186, 66-79. https://doi.org/10.1016/j.lfs.2017.08.006 https://pubmed.ncbi.nlm.nih.gov/28797793/
- Huang, B. S., Huang, S. C., Chen, F. H., Chang, Y., Mei, H. F., Huang, H. Y., Chen, W. Y., & Pang, J. S. (2022). Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Life sciences, 310, 121072. https://doi.org/10.1016/j.lfs.2022.121072 https://pubmed.ncbi.nlm.nih.gov/36228773/
- Ilic S., Drmic D., Franjic S., Kolenc D., Coric M., Brcic L., Klicek R., Radic B., Sever M., Djuzel V., Filipovic M., Djakovic Z., Stambolija V., Blagaic A.B., Zoricic I., Gjurasin M., Stupnisek M., Romic Z., Zarkovic K., Dzidic S., Seiwerth S., Sikiric P. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci. 2011;88(11-12):535–542. [http://dx.doi.org/10.1016/j.lfs.2011.01.015]. [PMID: 21295044]. [PubMed] [Google Scholar]
- Strbe, S., Gojkovic, S., Krezic, I., Zizek, H., Vranes, H., Barisic, I., Strinic, D., Orct, T., Vukojevic, J., Ilic, S., Lovric, E., Muzinic, D., Kolenc, D., Filipčić, I., Zoricic, Z., Marcinko, D., Boban Blagaic, A., Skrtic, A., Seiwerth, S., & Sikiric, P. (2021). Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157. Biomedicines, 9(11), 1506. https://doi.org/10.3390/biomedicines9111506 https://pubmed.ncbi.nlm.nih.gov/34829735/
- Prkacin, I., Separovic, J., Aralicia, G., Perovic, D., Gjurasin, M., Lovric-Bencic, M., Stancic-Rokotov, D., Staresinic, M., Anic, T., Mikus, D., Sikiric, P., Seiwerth, S., Mise, S., Rotkvic, I., Jagic, V., Rucman, R., Petek, M., Turkovic, B., Marovic, A., Sebecic, B., … Kokic, N. (2001). Portal hypertension and liver lesions in chronically alcohol-drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. Journal of physiology, Paris, 95(1-6), 315-324. https://doi.org/10.1016/s0928-4257(01)00044-4 https://pubmed.ncbi.nlm.nih.gov/11595456/
- Zivanovic-Posilovic, G., Balenovic, D., Barisic, I., Strinic, D., Stambolija, V., Udovicic, M., Uzun, S., Drmic, D., Vlainic, J., Bencic, M. L., Sindic, A., Seiwerth, S., & Sikiric, P. (2016). Stable gastric pentadecapeptide BPC 157 and bupivacaine. European journal of pharmacology, 793, 56-65. https://doi.org/10.1016/j.ejphar.2016.10.035 https://pubmed.ncbi.nlm.nih.gov/27815173/
- Medvidovic-Grubisic, M., Stambolija, V., Kolenc, D., Katancic, J., Murselovic, T., Plestina-Borjan, I., Strbe, S., Drmic, D., Barisic, I., Sindic, A., Seiwerth, S., & Sikiric, P. (2017). Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen. Inflammopharmacology, 25(4), 439–449. https://doi.org/10.1007/s10787-017-0323-6 https://pubmed.ncbi.nlm.nih.gov/28210905/
- Ilic S., Drmic D., Zarkovic K., Kolenc D., Coric M., Brcic L., Klicek R., Radic B., Sever M., Djuzel V., Ivica M., Boban Blagaic A., Zoricic Z., Anic T., Zoricic I., Djidic S., Seiwerth S., Sikiric P. High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736). J. Physiol. Pharmacol. 2010;61(2):241–250. [PMID: 20436226]. [PubMed] [Google Scholar]
- Ilic, S., Drmic, D., Franjic, S., Kolenc, D., Coric, M., Brcic, L., Klicek, R., Radic, B., Sever, M., Djuzel, V., Filipovic, M., Djakovic, Z., Stambolija, V., Blagaic, A. B., Zoricic, I., Gjurasin, M., Stupnisek, M., Romic, Z., Zarkovic, K., Dzidic, S., … Sikiric, P. (2011). Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sciences, 88(11-12), 535–542. https://doi.org/10.1016/j.lfs.2011.01.015 https://pubmed.ncbi.nlm.nih.gov/21295044/
- Ilic, S., Brcic, I., Mester, M., Filipovic, M., Sever, M., Barisic, I., Radic, B., Zoricic, Z., Bilic, V., Berkopic, L., Brcic, L., Kolenc, D., Romic, Z., Pazanin, L., Seiwerth, S., & Sikiric, P. (2009). Overdose of insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 60 Suppl 7, 107-114. https://pubmed.ncbi.nlm.nih.gov/20388953/
- Ilic, S., Drmic, D., Zarkovic, K., Kolenc, D., Brcic, L., Radic, B., Djuzel, V., Blagaic, A. B., Romic, Z., Dzidic, S., Kalogjera, L., Seiwerth, S., & Sikiric, P. (2011). Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. European journal of pharmacology, 667(1-3), 322-329. https://doi.org/10.1016/j.ejphar.2011.05.038 https://pubmed.ncbi.nlm.nih.gov/21645505/
- Sikiric, P., Jelovac, N., Jelovac-Gjeldum, A., Dodig, G., Staresinic, M., Anic, T., Zoricic, I., Rak, D., Perovic, D., Aralica, G., Buljat, G., Prkacin, I., Lovric-Bencic, M., Separovic, J., Seiwerth, S., Rucman, R., Petek, M., Turkovic, B., Ziger, T., Boban-Blagaic, A., … Babic, S. (2002). Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavioral disturbances. Acta pharmacologica Sinica, 23(5), 412-422. https://pubmed.ncbi.nlm.nih.gov/11978191/
- Klicek, R., Kolenc, D., Suran, J., Drmic, D., Brcic, L., Aralica, G., Sever, M., Holjevac, J., Radic, B., Turudic, T., Kokot, A., Patrlj, L., Rucman, R., Seiwerth, S., & Sikiric, P. (2013). Stabilem gastrijskim pentadecapeptid BPC 157 izliječio je cisteamin-kolitis te colon-colon-anastomozu, a protivuje se ozljedama mozga uzrokovanim cuprizonom te motoričkim poteškoćama. Journal of physiology and pharmacology : službeni časopis poljske fiziološke udruge, 64(5), 597–612. https://pubmed.ncbi.nlm.nih.gov/24304574/
- Sever, M., Klicek, R., Radic, B., Brcic, L., Brcic, I., Zoricic, I., Drmic, D., Ivica, M., Barisic, I., Ilic, S., Berkopic, L., Blagaic, A. B., Coric, M., Kolenc, D., Vrcic, H., Anic, T., Seiwerth, S., & Sikiric, P. (2009). Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Digestive diseases and sciences, 54(10), 2070–2083. https://doi.org/10.1007/s10620-008-0598-y https://pubmed.ncbi.nlm.nih.gov/19093208/
- Drmic, D., Samara, M., Vidovic, T., Malekinusic, D., Antunovic, M., Vrdoljak, B., Ruzman, J., Milkovic Perisa, M., Horvat Pavlov, K., Jeyakumar, J., Seiwerth, S., & Sikiric, P. (2018). Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine. World journal of gastroenterology, 24(48), 5462–5476. https://doi.org/10.3748/wjg.v24.i48.5462 https://pubmed.ncbi.nlm.nih.gov/30622376/
- Sikiric, P., Gojkovic, S., Krezic, I., Smoday, I. M., Kalogjera, L., Zizek, H., Oroz, K., Vranes, H., Vukovic, V., Labidi, M., Strbe, S., Baketic Oreskovic, L., Sever, M., Tepes, M., Knezevic, M., Barisic, I., Blagaic, V., Vlainic, J., Dobric, I., Staresinic, M., … Seiwerth, S. (2023). Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel, Switzerland), 16(5), 676. https://doi.org/10.3390/ph16050676 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224484/
- Park, J. M., Lee, H. J., Sikiric, P., & Hahm, K. B. (2020). BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Current pharmaceutical design, 26(25), 2971-2981. https://doi.org/10.2174/1381612826666200523180301 https://pubmed.ncbi.nlm.nih.gov/32445447/
- Sikiric, P., Drmic, D., Sever, M., Klicek, R., Blagaic, A. B., Tvrdeic, A., Kralj, T., Kovac, K. K., Vukojevic, J., Siroglavic, M., Gojkovic, S., Krezic, I., Pavlov, K. H., Rasic, D., Mirkovic, I., Kokot, A., Skrtic, A., & Seiwerth, S. (2020). Fistulas healing. Stable gastric pentadecapeptide BPC 157 therapy. Current pharmaceutical design, 26(25), 2991–3000. https://doi.org/10.2174/1381612826666200424180139 https://pubmed.ncbi.nlm.nih.gov/32329684/
- Xue, X. C., Wu, Y. J., Gao, M. T., Li, W. G., Zhao, N., Wang, Z. L., Bao, C. J., Yan, Z., & Zhang, Y. Q. (2004). Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World journal of gastroenterology, 10(7), 1032-1036. https://doi.org/10.3748/wjg.v10.i7.1032 https://pubmed.ncbi.nlm.nih.gov/15052688/
- Sikiric, P., Seiwerth, S., Grabarevic, Z., Petek, M., Rucman, R., Turkovic, B., Rotkvic, I., Jagic, V., Duvnjak, M., & Mise, S. (1994). The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sciences, 54(5), PL63–PL68. https://doi.org/10.1016/0024-3205(94)00796-9 https://pubmed.ncbi.nlm.nih.gov/7904712/
- Sikiric, P., Seiwerth, S., Aralica, G., Perovic, D., Staresinic, M., Anic, T., Gjurasin, M., Prkacin, I., Separovic, J., Stancic-Rokotov, D., Lovric-Bencic, M., Mikus, D., Turkovic, B., Rotkvic, I., Mise, S., Rucman, R., Petek, M., Ziger, T., Sebecic, B., Ivasovic, Z., ... Sjekavica, I. (2001). Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat. Journal of physiology, Paris, 95(1-6), 283-288. https://doi.org/10.1016/s0928-4257(01)00039-0 https://pubmed.ncbi.nlm.nih.gov/11595451/
- Stancic-Rokotov, D., Sikiric, P., Seiwerth, S., Slobodnjak, Z., Aralica, J., Aralica, G., Perovic, D., Anic, T., Zoricic, I., Buljat, G., Prkacin, I., Gjurasin, M., Rucman, R., Petek, M., Turkovic, B., Ivasovic, Z., Jagic, V., Staresinic, M., & Boban-Blagaic, A. (2001). Ethanol gastric lesion aggravated by lung injury in rat. Therapy effect of antiulcer agents. Journal of physiology, Paris, 95(1-6), 289-293. https://doi.org/10.1016/s0928-4257(01)00040-7 https://pubmed.ncbi.nlm.nih.gov/11595452/
- Stancic-Rokotov, D., Slobodnjak, Z., Aralica, J., Aralica, G., Perovic, D., Staresinic, M., Gjurasin, M., Anic, T., Zoricic, I., Buljat, G., Prkacin, I., Sikiric, P., Seiwerth, S., Rucman, R., Petek, M., Turkovic, B., Kokic, N., Jagic, V., & Boban-Blagaic, A. (2001). Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats. Journal of physiology, Paris, 95(1-6), 303–308. https://doi.org/10.1016/s0928-4257(01)00042-0 https://pubmed.ncbi.nlm.nih.gov/11595454/
- Petrovic, I., Dobric, I., Drmic, D., Sever, M., Klicek, R., Radic, B., Brcic, L., Kolenc, D., Zlatar, M., Kunjko, K., Jurcic, D., Martinac, M., Rasic, Z., Boban Blagaic, A., Romic, Z., Seiwerth, S., & Sikiric, P. (2011). BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 62(5), 527-534. https://pubmed.ncbi.nlm.nih.gov/22204800/
- Dobric, I., Drvis, P., Petrovic, I., Shejbal, D., Brcic, L., Blagaic, A. B., Batelja, L., Sever, M., Kokic, N., Tonkic, A., Zoricic, I., Mise, S., Staresinic, M., Radic, B., Jakir, A., Babel, J., Ilic, S., Vuksic, T., Jelic, I., Anic, T., … Sikiric, P. (2007). Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157. Journal of pharmacological sciences, 104(1), 7-18. https://doi.org/10.1254/jphs.fp0061322 https://pubmed.ncbi.nlm.nih.gov/17452811/
- Gojkovic, S., Krezic, I., Vranes, H., Zizek, H., Drmic, D., Batelja Vuletic, L., Milavic, M., Sikiric, S., Stilinovic, I., Simeon, P., Knezevic, M., Kolak, T., Tepes, M., Simonji, K., Strbe, S., Nikolac Gabaj, N., Barisic, I., Oreskovic, E. G., Lovric, E., Kokot, A., … Sikiric, P. (2021). Robertov intrakranični model gastrointestinalnih lezij uzrokovanih alkoholom kao eskaliranog općeg perifernog i centralnog sindroma, zaustavljen stabilnim gastrointestinalnim pentadekapeptidom BPC 157. Biomedicines, 9(10), 1300. https://doi.org/10.3390/biomedicines9101300 https://pubmed.ncbi.nlm.nih.gov/34680419/
- Wang, X. Y., Qu, M., Duan, R., Shi, D., Jin, L., Gao, J., Wood, J. D., Li, J., & Wang, G. D. (2019). Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells. Neuroscience bulletin, 35(1), 167-170. https://doi.org/10.1007/s12264-018-0269-8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357276/
- Baric, M., Sever, A. Z., Vuletic, L. B., Rasic, Z., Sever, M., Drmic, D., Pavelic-Turudic, T., Sucic, M., Vrcic, H., Seiwerth, S., & Sikiric, P. (2016). Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats. Life sciences, 148, 63-70. https://doi.org/10.1016/j.lfs.2016.02.029 https://pubmed.ncbi.nlm.nih.gov/26872976/
- Bedekovic, V., Mise, S., Anic, T., Staresinic, M., Gjurasin, M., Kopljar, M., Kalogjera, L., Drvis, P., Boban Blagaic, A., Batelja, L., Seiwerth, S., & Sikiric, P. (2003). Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy. European journal of pharmacology, 477(1), 73-80. https://doi.org/10.1016/j.ejphar.2003.08.013 https://pubmed.ncbi.nlm.nih.gov/14512101/
- Prkacin, I., Separovic, J., Aralicia, G., Perovic, D., Gjurasin, M., Lovric-Bencic, M., Stancic-Rokotov, D., Staresinic, M., Anic, T., Mikus, D., Sikiric, P., Seiwerth, S., Mise, S., Rotkvic, I., Jagic, V., Rucman, R., Petek, M., Turkovic, B., Marovic, A., Sebecic, B., … Kokic, N. (2001). Portal hypertension and liver lesions in chronically alcohol-drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. Journal of physiology, Paris, 95(1-6), 315-324. https://doi.org/10.1016/s0928-4257(01)00044-4 https://pubmed.ncbi.nlm.nih.gov/11595456/
- Klicek, R., Sever, M., Radic, B., Drmic, D., Kocman, I., Zoricic, I., Vuksic, T., Ivica, M., Barisic, I., Ilic, S., Berkopic, L., Vrcic, H., Brcic, L., Blagaic, A. B., Coric, M., Brcic, I., Rokotov, D. S., Anic, T., Seiwerth, S., & Sikiric, P. (2008). Pentadecapeptide BPC 157, in klinischen Studien als Therapie bei entzündlichen Darmerkrankungen (PL14736), ist bei der Heilung von kolocutanen Fisteln bei Ratten wirksam: Rolle des Stickstoffmonoxid-Systems. Journal of pharmacological sciences, 108(1), 7–17. https://doi.org/10.1254/jphs.fp0072161 https://pubmed.ncbi.nlm.nih.gov/18818478/
- Prkacin, I., Separovic, J., Aralicia, G., Perovic, D., Gjurasin, M., Lovric-Bencic, M., Stancic-Rokotov, D., Staresinic, M., Anic, T., Mikus, D., Sikiric, P., Seiwerth, S., Mise, S., Rotkvic, I., Jagic, V., Rucman, R., Petek, M., Turkovic, B., Marovic, A., Sebecic, B., … Kokic, N. (2001). Portal hypertension and liver lesions in chronically alcohol-drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. Journal of physiology, Paris, 95(1-6), 315-324. https://doi.org/10.1016/s0928-4257(01)00044-4 https://pubmed.ncbi.nlm.nih.gov/11595456/
- Gojkovic, S., Krezic, I., Vrdoljak, B., Malekinusic, D., Barisic, I., Petrovic, A., Horvat Pavlov, K., Kolovrat, M., Duzel, A., Knezevic, M., Kasnik Kovac, K., Drmic, D., Batelja Vuletic, L., Kokot, A., Boban Blagaic, A., Seiwerth, S., & Sikiric, P. (2020). Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats. World journal of gastrointestinal pathophysiology, 11(1), 1-19. https://doi.org/10.4291/wjgp.v11.i1.1 https://pubmed.ncbi.nlm.nih.gov/32226643/
- Kolovrat, M., Gojkovic, S., Krezic, I., Malekinusic, D., Vrdoljak, B., Kasnik Kovac, K., Kralj, T., Drmic, D., Barisic, I., Horvat Pavlov, K., Petrovic, A., Duzel, A., Knezevic, M., Mirkovic, I., Kokot, A., Boban Blagaic, A., Seiwerth, S., & Sikiric, P. (2020). Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. World journal of hepatology, 12(5), 184-206. https://doi.org/10.4254/wjh.v12.i5.184 https://pubmed.ncbi.nlm.nih.gov/32547687/
- Sever, A. Z., Sever, M., Vidovic, T., Lojo, N., Kolenc, D., Vuletic, L. B., Drmic, D., Kokot, A., Zoricic, I., Coric, M., Vlainic, J., Poljak, L., Seiwerth, S., & Sikiric, P. (2019). Stable gastric pentadecapeptide BPC 157 in the therapy of rats with bile duct ligation. European journal of pharmacology, 847, 130-142. https://doi.org/10.1016/j.ejphar.2019.01.030 https://pubmed.ncbi.nlm.nih.gov/30690000/
- Sikirić, P., Mazul, B., Seiwerth, S., Grabarević, Z., Rucman, R., Petek, M., Jagić, V., Turković, B., Rotkvić, I., Mise, S., Zoricić, I., Jurina, L., Konjevoda, P., Hanzevacki, M., Gjurasin, M., Separović, J., Ljubanović, D., Artuković, B., Bratulić, M., Tisljar, M., … Sumajstorcić, J. (1997). Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Digestive diseases and sciences, 42(3), 661-671. https://doi.org/10.1023/a:1018880000644 https://pubmed.ncbi.nlm.nih.gov/9073154/
- Kralj, T., Kokot, A., Zlatar, M., Masnec, S., Kasnik Kovac, K., Milkovic Perisa, M., Batelja Vuletic, L., Giljanovic, A., Strbe, S., Sikiric, S., Balog, S., Sontacchi, B., Sontacchi, D., Buljan, M., Lovric, E., Boban Blagaic, A., Skrtic, A., Seiwerth, S., & Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines, 10(1), 89. https://doi.org/10.3390/biomedicines10010089 https://pubmed.ncbi.nlm.nih.gov/35052769/
- Lazić, R., Gabrić, N., Dekaris, I., Bosnar, D., Boban-Blagaić, A., & Sikirić, P. (2005). Gastric pentadecapeptide BPC 157 promotes corneal epithelial defect healing in rats. Collegium anthropologicum, 29(1), 321-325. https://pubmed.ncbi.nlm.nih.gov/16117343/
- Zlatar, M., Kokot, A., Vuletic, L. B., Masnec, S., Kralj, T., Perisa, M. M., Barisic, I., Radic, B., Milanovic, K., Drmic, D., Seiwerth, S., & Sikiric, P. (2021). BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats. Frontiers in pharmacology, 12, 632295. https://doi.org/10.3389/fphar.2021.632295 https://pubmed.ncbi.nlm.nih.gov/34177567/
- Masnec, S., Kokot, A., Zlatar, M., Kalauz, M., Kunjko, K., Radic, B., Klicek, R., Drmic, D., Lazic, R., Brcic, L., Radic, R., Ivekovic, R., Seiwerth, S., & Sikiric, P. (2015). Perforating corneal injury in rat and pentadecapeptide BPC 157. Experimental eye research, 136, 9-15. https://doi.org/10.1016/j.exer.2015.04.016 https://pubmed.ncbi.nlm.nih.gov/25912999/
- Lee, E., & Padgett, B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine, 27(4), 8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
- Jung, Y. H., Kim, H., Kim, H., Kim, E., Baik, J., & Kang, H. (2022). The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. Journal of dental anaesthesia and pain medicine, 22(2), 97-105. https://doi.org/10.17245/jdapm.2022.22.2.97 https://pubmed.ncbi.nlm.nih.gov/35449779/
- Sikiric, P., Seiwerth, S., Grabarevic, Z., Rucman, R., Petek, M., Jagic, V., Turkovic, B., Rotkvic, I., Mise, S., Zoricic, I., Konjevoda, P., Perovic, D., Simicevic, V., Separovic, J., Hanzevacki, M., Ljubanovic, D., Artukovic, B., Bratulic, M., Tisljar, M., Rekic, B., … Buljat, G. (1997). Pentadecapeptide BPC 157 pozitivno vpliva tako pri gastrointestinalnih lezijah, ki jih povzdiguje nesteroide protivnetna zdravila, kot pri adjuvantnem artritisu pri podganah. Journal of Physiology, Pariz, 91(3-5), 113–122. https://doi.org/10.1016/s0928-4257(97)89474-0 https://pubmed.ncbi.nlm.nih.gov/9403784/
- Rasic, D., Zenko Sever, A., Rasic, F., Strbe, S., Rasic, Z., Djuzel, A., Duplancic, B., Boban Blagaic, A., Skrtic, A., Seiwerth, S., Sikiric, P., & Sever, M. (2021). Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats. Biomedicines, 9(9), 1206. https://doi.org/10.3390/biomedicines9091206 https://pubmed.ncbi.nlm.nih.gov/34572392/
- Tkalcević, V. I., Cuzić, S., Brajsa, K., Mildner, B., Bokulić, A., Situm, K., Perović, D., Glojnarić, I., & Parnham, M. J. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European journal of pharmacology, 570(1-3), 212-221. https://doi.org/10.1016/j.ejphar.2007.05.072 https://pubmed.ncbi.nlm.nih.gov/17628536/
- Sucic, M., Luetic, K., Jandric, I., Drmic, D., Sever, A. Z., Vuletic, L. B., Halle, Z. B., Strinic, D., Kokot, A., Seiwerth, R. S., Zoricic, I., Blagaic, A. B., Seiwerth, S., & Sikiric, P. (2019). Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME. European journal of pharmacology, 861, 172593. https://doi.org/10.1016/j.ejphar.2019.172593 https://pubmed.ncbi.nlm.nih.gov/31401154/
- Smoday, I. M., Petrovic, I., Kalogjera, L., Vranes, H., Zizek, H., Krezic, I., Gojkovic, S., Skorak, I., Hriberski, K., Brizic, I., Kubat, M., Strbe, S., Barisic, I., Sola, M., Lovric, E., Lozic, M., Boban Blagaic, A., Skrtic, A., Seiwerth, S., & Sikiric, P. (2022). Therapeutic effect of the stable gastric pentadecapeptide BPC 157 on acute pancreatitis as vascular failure-induced severe peripheral and central syndrome in rats. Biomedicines, 10(6), 1299. https://doi.org/10.3390/biomedicines10061299 https://pubmed.ncbi.nlm.nih.gov/35740321/